Psychiatric drug developer Zynerba Pharmaceuticals and members of its board of directors were hit with a shareholder lawsuit on Sept. 8 in Eastern Pennsylvania District Court in connection with the company’s proposed acquisition by Harmony Biosciences Holdings. The suit, filed by Brodsky & Smith on behalf of Scott Wilson, claims that the company’s proxy statement in support of the proposed transaction omits or misrepresents material information including conflicts of interest for Zynerba’s management. Counsel have not yet appeared for the defendants. The case is 2:23-cv-03502, Wilson v. Zynerba Pharmaceuticals, Inc.
This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
